Nhau News Online News that is accurate, reliable, trustworthy!!
By Judith Matanire
Cimas MEDLABS, the leading provider of diagnostic and medical laboratory services in the country, has initiated a comprehensive project aimed at renovating and equipping all its laboratories. This endeavor seeks to ensure that tests are conducted onsite, facilitating timely results delivery across Zimbabwe.
Designated as a Health Institution by the Medical Laboratory and Clinical Scientists Association of Zimbabwe, Cimas MEDLABS offers a wide range of pathology tests, including haematology, biochemistry, histology, microbiology, viral load, and bone marrow aspirate, catering to both Cimas members and non-member patients referred by primary healthcare clinics and private doctors.
Dr. Tsitsi Moyo, the Cimas Group Medical Advisor and Head of Diagnostics, announced the project during a media tour of Cimas MEDLABS in Harare, held as part of the commemoration of Medical Laboratory Professionals Week (Lab Week) 2024.
Dr. Moyo emphasized that the initiative aims to decrease the number of tests referred to the Central Laboratory in Harare, enhancing efficiency and accessibility of diagnostic services nationwide.
“Our goal is to ensure that individuals in Zimbabwe have access to top-tier diagnostic services that are not only accurate but also delivered in a timely manner,” Dr Moyo stated. “By investing in the renovation and re-equipment of our laboratories, we are taking a significant step towards achieving this objective and fulfilling our commitment to the health and well-being of our community.”
Lab Week, an annual celebration honoring the contributions of medical laboratory professionals, coincides with this announcement, themed “The Lab is Everything” for the 2024 edition. Reflecting on Cimas MEDLABS’ journey since its establishment in 1985, Moyo highlighted the remarkable journey of Cimas MEDLABS, evolving from a single laboratory to eight strategically located facilities nationwide, including branches, satellite laboratories, and collection points, collectively serving a significant volume of pathology tests throughout Zimbabwe. Moyo emphasized the institution’s forthcoming acquisition of a state-of-the-art gene sequencer, marking a significant milestone in its advancement. The addition of the gene sequencer underscores Cimas MEDLABS’ commitment to advancing genetic research and personalized medicine.
Dr. Moyo emphasized the importance of incorporating the African genome into healthcare practices, from diagnostics to pharmaceuticals, through groundbreaking research and technology.
Furthermore, Dr. Moyo emphasized Cimas MEDLABS’ dedication to nurturing future scientists by offering industrial attachments and internships to newly qualified professionals, providing them with real-world work exposure and state-of-the-art equipment.
Cimas MEDLABS reaffirmed its role not only as a clinical diagnostic and testing entity but also as a key contributor to medical research and scientific discovery in Zimbabwe and beyond. *Nhau/Indaba*
